Financial Performance - The company's operating revenue for Q3 2024 was ¥172,965,736.96, representing a year-on-year increase of 17.32%[2] - Net profit attributable to shareholders for Q3 2024 was ¥21,307,271.49, a significant increase of 6,028.76% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥7,337,339.52, up by 181.78% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.0579, reflecting a year-on-year increase of 6,003.93%[2] - Net profit attributable to shareholders for the year-to-date period was ¥30,770,165.28, showing an increase of 807.59% compared to the same period last year[2] - Total operating revenue for the first three quarters of 2024 reached ¥418,931,219.77, an increase of 4.3% compared to ¥402,805,031.75 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was ¥30,770,165.28, significantly up from ¥3,390,298.30 in 2023, marking an increase of 807.4%[16] - Basic earnings per share for the first three quarters of 2024 were ¥0.0840, compared to ¥0.0091 in 2023, reflecting an increase of 823.1%[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,859,779,651.33, a decrease of 11.80% compared to the end of the previous year[3] - As of September 30, 2024, the company's total assets amounted to approximately CNY 1.86 billion, a decrease from CNY 2.11 billion at the end of 2023, reflecting a decline of about 11.7%[11] - The company's cash and cash equivalents decreased significantly to CNY 260.92 million from CNY 620.45 million, representing a decline of approximately 58.1%[11] - Total current liabilities decreased to CNY 321.63 million from CNY 446.91 million, a reduction of about 28.1%[12] - The company's non-current liabilities decreased to CNY 18.45 million from CNY 23.22 million, a decline of approximately 20.1%[13] - The total equity attributable to shareholders decreased to CNY 1.52 billion from CNY 1.64 billion, reflecting a decrease of about 7.3%[13] Cash Flow - The company reported a net cash flow from operating activities of ¥22,340,708.43 for Q3 2024, a slight decrease of 0.45%[2] - The net cash flow from operating activities for the first three quarters of 2024 was -¥758,663.64, an improvement from -¥11,949,314.66 in 2023[17] - Cash outflow from investment activities totaled ¥854,957,088.85, a decrease from ¥1,495,491,250.16 in the previous period, resulting in a net cash flow from investment activities of -¥246,291,188.28 compared to -¥48,514,725.24[18] - Cash inflow from financing activities was ¥298,258,736.45, up from ¥175,405,390.44, while cash outflow from financing activities increased to ¥414,323,983.23 from ¥108,039,180.24, leading to a net cash flow from financing activities of -¥116,065,246.78 compared to ¥67,366,210.20[18] - The net increase in cash and cash equivalents was -¥363,115,098.70, contrasting with an increase of ¥6,902,170.30 in the previous period[18] - The ending balance of cash and cash equivalents was ¥256,617,682.97, down from ¥439,540,865.47[18] - The company reported a significant cash payment of ¥665,068,253.54 related to investment activities, compared to ¥1,313,316,947.02 in the previous period[18] Other Financial Metrics - The weighted average return on equity for Q3 2024 was 1.35%, an increase of 1.32 percentage points year-on-year[3] - Non-recurring gains for the current period totaled ¥13,969,931.97, with government subsidies contributing ¥3,462,487.62[5] - Research and development expenses increased to ¥20,283,032.38 in 2024, up from ¥8,860,272.09 in 2023, reflecting a growth of 128.5%[15] - Operating profit for the first three quarters of 2024 was ¥32,854,192.90, compared to ¥20,556,716.00 in 2023, representing a growth of 59.7%[15] - Total costs for the first three quarters of 2024 were ¥402,086,823.47, slightly up from ¥399,583,076.61 in 2023, indicating a marginal increase of 0.4%[15] - The company reported a significant increase in investment income, which rose to ¥31,783,964.82 in 2024 from ¥17,745,088.26 in 2023, an increase of 79.3%[15] - The company recorded a decrease in tax expenses to ¥1,687,076.42 in 2024 from -¥1,454,264.77 in 2023, indicating a positive shift in tax liabilities[16] - Other income increased significantly to ¥4,378,019.03 in 2024 from ¥222,350.42 in 2023, marking a growth of 1,967.5%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,641[8] - The company has not reported any changes in the participation of major shareholders in margin trading and securities lending activities[10] - The company has not identified any significant changes in its operational situation during the reporting period[10] Accounting Standards - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[19]

证券代码：600080 股票简称：金花股份 编号：临 2024-049 金花企业（集团）股份有限公司 关于公司进行融资租赁的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 主要内容：金花企业（集团）股份有限公司 （以下简称"公司"）拟 以公司自有医药生产制造设备为租赁标的，与浙江浙银金融租赁股份有限公司 （以下简称"浙银金租"）开展融资租赁售后回租业务，融资总额不超过 2500 万元，主要用于设备采购，融资期限 24 个月。 本次融资租赁业务未构成关联交易，不构成《上市公司重大资产重组 管理办法》规定的重大资产重组。 该事项已经公司第十届董事会第十一次会议审议通过，无需提交股东 大会审议。 公司于 2024 年 10 月 17 日以通讯方式召开第十届董事会第十一次会议，审 议通过了《关于公司进行融资租赁的议案》。具体内容如下： 一、本次融资租赁概述 为拓宽融资渠道，确保资金需求，公司拟以公司自有医药生产制造设备为租 赁标的，与浙银金租开展融资租赁售后回租业务，融资总额不超过 2500 万元， 主要用 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 证券代码：600080 证券简称：金花股份 公告编号：临 2024-048 会议召开方式：上证路演中心网络互动 金花企业(集团)股份有限公司 投资者可于 2024 年 09 月 13 日(星期五)至 09 月 23 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 irm@ginwa.com.cn 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 关于召开 2024 年半年度业绩说明会的公告 金花企业(集团)股份有限公司（以下简称"公司"）已于 2024 年 8 月 17 日发布公司 2024 年半年度报告，为便于广大投资者更全面深 入地了解公司 2024 年半年度经营成果、财务状况，公司计划于 2024 年 09 月 24 日下午 16:00-17:00 举行 2024 年半年度业绩说明会，就 投资者关心的问题进行交流。 董事会秘书：孙明 独立董事 ...

邢雅江，金花企业（集团）股份有限公司时任董事长。 上 海 证 券 交 易 所 上证公监函〔2024〕0196 号 关于对金花企业（集团）股份有限公司及 有关责任人予以监管警示的决定 当事人： 金花企业（集团）股份有限公司，A 股证券简称：金花股份，A 股证券代码：600080； 鉴于上述违规事实和情节，根据《股票上市规则》第 13.2.2 条 和《上海证券交易所纪律处分和监管措施实施办法》等有关规定， 我部作出如下监管措施决定： 对金花企业（集团）股份有限公司及时任董事长邢雅江予以监 管警示。 根据《上海证券交易所纪律处分和监管措施实施办法》，请你公 司及董事、监事和高级管理人员（以下简称董监高人员）采取有效 措施对相关违规事项进行整改，并结合本决定书指出的违规事项， 就公司信息披露及规范运作中存在的合规隐患进行深入排查，制定 针对性的防范措施，切实提高公司信息披露和规范运作水平。请你 公司在收到本决定书后一个月内，向我部提交经全体董监高人员签 字确认的整改报告。 你公司及董监高人员应当举一反三，避免此类问题再次发生。 公司应当严格按照法律、法规和《股票上市规则》的规定规范运作， 认真履行信息披露义务；董监高 ...

证券代码：600080 股票简称：金花股份 编号：临 2024-046 金花企业（集团）股份有限公司 关于收到中国证券监督管理委员会陕西监管局 经核查举报线索，发现你公司董事长邢雅江因涉嫌犯罪于 2024 年 4 月至 7 月被公安机关采取了取保候审的刑事强制措施。该事项属于应立即披露的重大事 件，但你公司至今未披露，违反了《上市公司信息披露管理办法》(证监会令第 182 号，以下简称《办法》)第二十二条第一款、第二款第一项的规定。邢雅江 作为上市公司董事长和事件当事人，违反了《办法》第三十三条第一款规定。 根据《办法》第五十二条规定，我局决定对你公司及邢雅江采取责令改正的 行政监管措施，责令你们在收到本决定书后立即披露邢雅江被采取刑事强制措施 的具体情况，说明事件起因、最新进展及对公司的影响等。你们应认真汲取教训， 严格遵守上市公司信息披露各项规定，杜绝此类行为再次发生，并自收到本决定 书之日起十五个工作日内分别向我局提交书面整改报告。 行政监管措施决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 金花企业 ...

金花企业（集团）股份有限公司（以下简称"公司"）于 2024 年 8 月 23 日 收到董事长邢雅江先生送达的《解除取保候审决定书》，知悉董事长邢雅江先生 于 2024 年 4 月 23 日至 2024 年 7 月 26 日期间被公安机关采取取保候审的措施， 具体情况如下： 一、事件的起因及进展 经公司向邢雅江先生核实，前期因其他人员涉嫌私自刻制与公司无关的其他 公司印章被公安机关立案调查，其向公安机关供述系邢雅江先生知悉并受其指 使，致使邢雅江先生成为涉案人员，西安市公安局鄠邑分局于 2024 年 4 月 23 日起决定对董事长邢雅江先生取保候审。 2024 年 7 月 26 日，西安市公安局鄠邑分局出具了《解除取保候审决定书》， 因指证邢雅江的证据发生变化，现有证据不能证实邢雅江有涉案嫌疑，根据《中 华人民共和国刑事诉讼法》第七十九条第二款之规定，决定予以解除取保候审。 证券代码：600080 股票简称：金花股份 编号：临 2024-047 金花企业(集团)股份有限公司 关于公司董事长被采取取保候审措施并收到解除取保候审 决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或 ...

Financial Performance - The company's operating revenue for the first half of 2024 was approximately CNY 245.97 million, a decrease of 3.68% compared to the same period last year[25]. - The net profit attributable to shareholders for the first half of 2024 was approximately CNY 9.46 million, an increase of 211.01% year-on-year[25]. - Basic earnings per share for the first half of 2024 were CNY 0.0261, representing a 218.20% increase compared to CNY 0.0082 in the same period last year[25]. - The weighted average return on net assets increased to 0.60%, up by 0.42 percentage points from the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 10.03 million yuan, a decrease of 42.39% compared to the previous year[41]. - The company reported a significant increase in investment income, which rose to CNY 29,401,390.85 from CNY 18,469,690.53, an increase of 59.5%[163]. - The company reported a total comprehensive income of CNY 1,097,818.35 for the first half of 2024, down from CNY 4,317,849.32 in the previous year[171]. Assets and Liabilities - Total assets at the end of the reporting period were approximately CNY 1.79 billion, down 15.21% compared to the previous year[25]. - The net assets attributable to shareholders at the end of the reporting period were approximately CNY 1.50 billion, a decrease of 8.55% from the end of the previous year[25]. - Total liabilities decreased to CNY 288,448,334.75 from CNY 455,489,966.11, indicating a reduction of 36.7%[158]. - The company's total equity stood at CNY 1,505,660,295.42, down from CNY 1,654,062,384.09, reflecting a decrease of 9.0%[158]. Cash Flow - The company reported a net cash flow from operating activities of CNY -23.10 million, indicating a decline in cash flow compared to CNY -34.39 million in the previous year[25]. - Cash flow from operating activities showed a net outflow of CNY 23,099,372.07, an improvement from a net outflow of CNY 34,391,321.39 in the same period last year[182]. - Cash inflow from financing activities was CNY 298,234,856.45, significantly higher than CNY 99,000,000.00 in the previous year, marking a 201.36% increase[182]. Research and Development - The company's research and development expenses increased by 60.93% to ¥8,421,920.46 from ¥5,233,339.12 year-on-year[57]. - Research and development expenses increased to CNY 8,421,920.46 in the first half of 2024, up from CNY 5,233,339.12 in the previous year, representing a growth of 60.5%[163]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of various drug types[35]. - The company has established a strong position in the pharmaceutical industry, focusing on orthopedics, immunology, and pediatrics, with key products like artificial tiger bone powder and Jintian Ge capsules recognized in 47 authoritative guidelines[42]. - The marketing strategy includes academic promotion and collaboration with authoritative organizations, enhancing clinical evidence and product application in medical institutions[44]. Compliance and Risk Management - The company is currently facing ongoing arbitration related to a guarantee provided by a former controlling shareholder, which has not yet been resolved[9]. - The company has established a risk management group to enhance safety management and ensure compliance with quality standards in production[53]. - The company is focusing on compliance management to reduce potential risks and protect its rights[56]. Environmental Management - The company has not reported any significant environmental issues or administrative penalties related to environmental protection during the reporting period[85]. - The company’s emissions of nitrogen oxides from combustion waste meet the required standards[85]. - The company has established a comprehensive environmental monitoring system, ensuring all pollutants are within the emission standards[95]. Shareholder and Equity Management - The company committed to not increasing its equity stake in the listed company for the next 12 months, based on market conditions and business development[100]. - The company has a plan to reduce its holdings of up to 3,982,690 shares, representing 1.07% of the total share capital, through block trading and centralized bidding within the next 12 months[103]. - The company has completed its commitment to not increase or decrease its equity stake in the listed company as of April 23, 2025[103].

金花企业（集团）股份有限公司 第十届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、 监事会会议召开情况 证券代码：600080 股票简称：金花股份 编号：临 2024-044 金花企业（集团）股份有限公司第十届监事会第七次会议通知于 2024 年 8 月 6 日以电子邮件及微信方式发出，会议于 2024 年 8 月 15 日以现场方式在公司 会议室召开。应出席监事 3 人,实际出席 3 人，会议由监事会主席马斌先生主持， 本次会议的召集召开符合《公司法》和《公司章程》的有关规定，经讨论表决， 通过如下决议。 二、监事会会议审议情况 （一）通过《公司 2024 年半年度报告及摘要》 表决情况：同意票 3 票，反对票 0 票，弃权票 0 票 （二）通过《关于公司 2024 年半年度报告审核意见》 表决情况：同意票 3 票，反对票 0 票，弃权票 0 票 根据中国证监会《公开发行证券的公司信息披露内容与格式准则第 3 号—半 年度报告的内容与格式》、《上海证券交易所股票上市规则》等有关法律、法规 ...

证券代码：600080 股票简称：金花股份 编号：临 2024-043 金花企业（集团）股份有限公司 第十届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 金花企业（集团）股份有限公司第十届董事会第十次会议通知于 2024 年 8 月 6 日以 电子邮件及微信方式发出，会议于 2024 年 8 月 15 日以现场和通讯结合的方式在公司会议 室召开。应出席董事 7 人，实际出席董事 7 人，其中现场出席董事 6 人，独立董事赵舸女 士以通讯方式参会。会议由董事长邢雅江先生主持，公司监事及高管人员列席会议。本次 会议符合《公司法》和《公司章程》的有关规定，经讨论表决，会议通过如下决议。 二、董事会会议审议情况 （一）通过《公司 2024 年半年度报告》及《2024 年半年度报告摘要》 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票 本议案已经第十届董事会审计委员会审议通过。 《2024 年半年度报告摘要》详见上海证券报及上海证券交易所网站；《2024 年半 年度报告 ...

证券代码：600080 股票简称： 金花股份 编号：临 2024-045 金花企业（集团）股份有限公司 关于公司2024 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担个别及连带责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证监会《关于核准金花企业（集团）股份有限公司非公开发行股票的批复》 （证监许可[2017]1648 号）核准，金花企业（集团）股份有限公司（以下简称"公司"） 发行股票 67,974,413 股（A 股），发行价格为人民币 9.38 元/股，本次发行募集资金总 额为人民币 637,599,993.94 元，扣除各项发行费用后，实际募集资金净额为人民币 628,780,819.60 元。瑞华会计师事务所（特殊普通合伙）已对上述募集资金的到位情况 进行了审验，并于 2018 年 3 月 22 日出具的《金花企业（集团）股份有限公司验资报告》 (瑞华验字[2018]61060001 号)审验确认。 | 项目 | 金额（元） | | --- | --- ...